Birth Defects Res A Clin Mol Teratol by Howley, Meredith M. et al.
Maternal Autoimmune Disease and Birth Defects in the National 
Birth Defects Prevention Study
Meredith M. Howley1,*, Marilyn L. Browne1,2, Alissa R. Van Zutphen1,2, Sandra D. 
Richardson1, Sarah J. Blossom3, Cheryl S. Broussard4, Suzan L. Carmichael5, and 
Charlotte M. Druschel1,2 for the National Birth Defects Prevention Study
1Congenital Malformations Registry, New York State Department of Health, Albany, New York
2Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, 
Rensselaer, New York
3Department of Pediatrics, Arkansas Children’s Hospital Research Institute, Little Rock, Arkansas
4Division of Birth Defects and Developmental Disabilities, National Center on Birth Defects and 
Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia
5Department of Pediatrics, Stanford University, Stanford, California
Abstract
Background—Little is known about the association between maternal autoimmune disease or its 
treatment and the risk of birth defects. We examined these associations using data from the 
National Birth Defects Prevention Study, a multi-site, population-based, case–control study.
Methods—Analyses included 25,116 case and 9897 unaffected control infants with estimated 
delivery dates between 1997 and 2009. Information on autoimmune disease, medication use, and 
other pregnancy exposures was collected by means of telephone interview. Adjusted odds ratios 
(ORs) and 95% confidence intervals (CIs) were estimated for birth defects with five or more 
exposed cases; crude ORs and exact 95% CIs were estimated for birth defects with three to four 
exposed cases.
Results—Autoimmune disease was reported by 373 mothers (279 case and 94 control mothers). 
The majority of birth defects evaluated were not associated with autoimmune disease; however, a 
statistically significant association between maternal autoimmune disease and encephalocele was 
observed (OR, 4.64; 95% CI, 1.95–11.04). Eighty-two mothers with autoimmune disease used an 
immune modifying/suppressing medication during pregnancy; this was associated with 
encephalocele (OR, 7.26; 95% CI, 1.37–24.61) and atrial septal defects (OR, 3.01; 95% CI, 1.16–
7.80).
Conclusion—Our findings suggest maternal autoimmune disease and treatment are not 
associated with the majority of birth defects, but may be associated with some defects, particularly 
encephalocele. Given the low prevalence of individual autoimmune diseases and the rare use of 
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specific medications, we were unable to examine associations of specific autoimmune diseases and 
medications with birth defects. Other studies are needed to confirm these findings.
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Introduction
Autoimmune diseases are common in the United States, and women of childbearing age are 
thought to be at the greatest risk (Cooper et al., 2009; Office of Women’s Health, 2010). 
There are well-established links between autoimmune disease and infertility, recurrent 
miscarriage, preterm birth, pre-eclampsia, and intrauterine growth restriction (Costedoat-
Chalumeau et al., 2004, 2005; Ornoy et al., 2004; Clancy et al., 2004; Carp et al., 2012; 
Twig et al., 2012; Tersigni et al., 2014). However, the literature is sparse in terms of the 
association between the presence of an autoimmune disease and the risk of birth defects.
Estimates of the association between autoimmune medications and specific birth defects are 
also sparse, consisting largely of case series and studies with small numbers of exposed 
infants. Recommendations for drug use during pregnancy vary, and limited information 
exists on the comparative safety during pregnancy of many immunosuppressive agents 
(Ostensen et al., 2006; Kim et al., 2014; Cooper et al., 2014). For example, methotrexate is 
used for cancer chemotherapy, as a treatment for a variety of autoimmune conditions, and as 
an abortifacient (Lloyd et al., 1999). It is known to have adverse fetal effects (Feldkamp and 
Carey, 1993; Lloyd et al., 1999; Piggott et al., 2011; Hyoun et al., 2012; Weber-
Schoendorfer et al., 2014; Kim et al., 2014; Dawson et al., 2014). The Food and Drug 
Administration lists methotrexate as contraindicated during pregnancy for women with 
psoriasis or rheumatoid arthritis; however, questions remain, with some suggesting that 
methotrexate is not toxic when used in low doses by pregnant women (Lewden et al., 2004; 
Visser et al., 2009; U.S. FDA, 2011; Kim et al., 2014; Weber-Schoendorfer et al., 2014). The 
picture of comparative safety for the majority of medications used for autoimmune disease 
remains similarly unclear.
We used data from the National Birth Defects Prevention Study (NBDPS), a large, multisite, 
population-based, case–control study, to examine the role of autoimmune disease and its 
treatment on the risk of birth defects.
Materials and Methods
The NBDPS began collecting data in 1997 (Reefhuis et al., 2015). Infants with 1 or more of 
30 different categories of major structural malformations (cases), excluding those attributed 
to a known chromosomal or single-gene abnormality, were ascertained through birth defects 
surveillance systems in 10 states (Arkansas, California, Georgia, Iowa, Massachusetts, North 
Carolina, New Jersey, New York, Texas, and Utah). Control infants were live unaffected 
births born in the same time period and geographic area as the cases, randomly selected 
from hospital records, birth certificates, or both. Each study site and the Centers for Disease 
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Control and Prevention obtained Institutional Review Board approval. Mothers provided 
informed consent.
This analysis includes births with estimated delivery dates from October 1997 through 
December 2009. The main analysis includes birth defects for which 100 or more cases were 
available for study. To avoid missing strong effects in small case groups, we conducted 
exploratory analyses of 15 birth defects with less than 100 infants, which included: truncus 
arteriosus, interrupted aortic arch (IAA) type a, IAA other/type b, double outlet right 
ventricle with transposition of the great arteries, conoventricular ventricular septal defects 
(VSD), tricuspid atresia, multiple VSD, other VSD, cerebellar hypoplasia, colonic atresia/
stenosis, bladder exstrophy, intercalary limb deficiency, unspecified limb deficiencies, 
cloacal exstrophy, and sacral agenesis.
Trained interviewers conducted computer-assisted telephone interviews with the mothers of 
case and control infants to collect information on demographics, pregnancy history, health 
conditions, and exposures before and during pregnancy. Mothers were asked about 
medications taken during the period from 3 months preconception through the end of 
pregnancy, and information was collected on timing, frequency, and duration of medication 
use. The Slone Epidemiology Center Drug Dictionary was used to code all reported 
medications. During the study period, 67.4% of eligible case mothers and 64.8% of eligible 
control mothers participated in the interview. A total of 38,009 mothers (27,809 cases and 
10,200 controls) completed the NBDPS interview during the study period.
Case inclusion criteria have been described previously (Reefhuis et al., 2015). Briefly, 
clinical geneticists reviewed and classified each case infant as having isolated, multiple, or 
complex birth defects (Rasmussen et al., 2003). Congenital heart defect (CHD) cases were 
further categorized as simple (a single CHD or CHD “entity”), association, or complex 
(Botto et al., 2007). CHD cases classified as atrial septal defects (ASD) not otherwise 
specified were likely ASD secundum type and were counted as such in the analysis (Botto et 
al., 2007).
In January 2006, data collection for VSD changed; the current analysis excludes VSDs 
diagnosed after 2005. Certain study sites did not ascertain cases during the entire study 
period for oral clefts and pulmonary valve stenosis, and muscular VSDs were included for 
the first year for sites participating from 1997 to 1998. When analyzing those defects, cases 
and controls were excluded for the study sites and years for which case ascertainment was 
incomplete. Microtia included dysplastic ear pinna and stenosis or atresia of external 
auditory canal. Infants with intestinal atresia limited to the duodenum were grouped and 
counted as duodenal atresias; other intestinal atresias (ileal, jejunal, and multiple intestinal 
atresias or stenosis) were counted as small intestinal atresias. Infants with esophageal or 
small intestinal atresia that occurred as a component of a VATER/VACTERL association 
defects were classified as having multiple defects. For hypospadias, only second- and third-
degree hypospadias cases were included; the control group was restricted to males. 
Congenital heart block is not a structural malformation and was not collected as part of 
NBDPS. However, we examined the frequency of congenital heart block occurring with an 
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eligible NBDPS defect, given the link between maternal autoimmune antibodies and birth 
defects (Costedoat-Chalumeau, 2005; Yan et al., 2012).
Mothers interviewed before 2006 were asked if they had “any other disease or illnesses that 
we have not already talked about, such as chronic disease, infectious disease, or sexually 
transmitted diseases.” Mothers interviewed in or after 2006 were asked if they had “any 
other chronic disease or illness that we have not talked about such as asthma, thyroid 
disease, an autoimmune disease, or other chronic or long-term diseases.” Information on 
autoimmune disease was also captured in comment fields throughout the interview. Maternal 
autoimmune disease status was compiled and manually reviewed by a study investigator, 
blinded to case/control status, who assigned infants to one of three mutually exclusive 
groups: (1) autoimmune disease, (2) possible autoimmune disease, or (3) no autoimmune 
disease.
Medications specifically used to treat autoimmune disease were manually reviewed for 
mothers classified with possible and no autoimmune disease. A vague description plus a 
report of a medication or procedure indicated specifically for an autoimmune condition was 
used to assign a more specific diagnosis in seven instances. For example, a diagnosis of 
ulcerative colitis was assigned for five mothers who reported “colitis,” which could have 
nonautoimmune etiologies, and reported taking mesalamine, which is used specifically for 
ulcerative colitis. Another diagnosis was confirmed for inflammatory bowel disease based 
on a report of an “inflammatory” disease and use of sulfasalazine. A diagnosis of 
rheumatoid arthritis was assigned based on a report of Bowers procedure and use of 
methotrexate. In two instances, the autoimmune diagnosis was made based on reported use 
of medication specifically used for autoimmune conditions in the absence of a reported 
autoimmune disease. One mother was assigned an inflammatory bowel disease diagnosis 
based on reported use of mesalamine. Another mother was assigned a multiple sclerosis 
diagnosis based on reported use of methotrexate and interferon beta-1b.
We further classified mothers with autoimmune disease as having systemic disease as 
opposed to organ-specific disease and conducted a sub-analysis restricted to systemic 
autoimmune disease and birth defects. While autoimmune diseases are broadly divided into 
systemic disease and not, the distinction is not always clear (Firestein et al., 2013). For this 
analysis, the following autoimmune diseases were considered systemic: antiphospholipid 
antibody syndrome; Crohn’s disease; ulcerative proctitis; ulcerative colitis; inflammatory 
bowel disease; psoriatic arthritis; systemic lupus erythematosus, scleroderma, Sjögren’s 
syndrome or another connective tissue disease; rheumatoid arthritis; and ankylosing 
spondylitis (Firestein et al., 2013).
To examine medications used to treat autoimmune disease, mothers with autoimmune 
disease were classified according to autoimmune medication use during the 3 months before 
through the end of pregnancy. Mutually exclusive categories were created and included: (1) 
mothers with any immune modifier/suppressant use (acitretin, azathioprine, 
cyclophosphamide, cyclosporine, hydroxychloroquine, hydroxyurea, mercaptopurine, 
mesalamine, methotrexate, methoxsalen, mycophenolate, rituximab, sulfasalazine, tumor 
necrosis factor inhibitors, or other biologic agents), (2) mothers with any glucocorticoid use 
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(except use of asthma medication fluticasone, beclomethasone, and mometasone) in the 
absence of immune modifiers/suppressants, and (3) mothers not treated with an immune 
modifier/suppressant, glucocorticoid, or thyroid medication. “Untreated” mothers could have 
taken a less specific anti-inflammatory medication for their autoimmune disease; in fact, 
47% of “untreated” mothers reported taking an nonsteroidal anti-inflammatory drug.
Covariates were identified a priori by directed acyclic graphs. Adjusted analyses controlled 
for maternal age at delivery (≤29, 30–34, ≥35 years), parity (≤1, ≥2 previous births), race/
ethnicity (non-Hispanic white, other), education (high school or less, more than high 
school), prepregnancy body mass index [(BMI) weight in kilograms/height in meters2; 
<18.5, 18.5–24.9, 25–29.9, ≥30], state of residence at birth, folic acid-containing supplement 
use 1 month preconception through the first month of pregnancy, and both alcohol 
consumption and cigarette smoking 1 month preconception through the third month of 
pregnancy.
To reduce etiologic heterogeneity within case groups, we excluded infants with a birth defect 
that was classified either as a complex sequence (a group of defects believed to be 
pathogenetically related, but for which the primary defect is not apparent) or classified as an 
uncommon CHD association. We included infants in case groups that consist primarily of 
complex defects such as heterotaxia with CHD and single ventricle defect, as well as infants 
in case groups that are common CHD associations (e.g., coarctation of the aorta and VSD). 
Infants of mothers who remained in the possible autoimmune disease category were also 
excluded from all analyses. Lastly, infants of mothers who reported pre-existing type 1 or 2 
diabetes were excluded because diabetes is a well-known risk factor for a variety of birth 
defects, and we wanted to separately examine other autoimmune conditions (Correa et al., 
2008).
For birth defects with five or more exposed cases, multivariable logistic regression models 
estimated the adjusted odds ratio (ORs) and 95% confidence intervals (CIs) for the 
association between maternal autoimmune disease and each birth defect, while controlling 
for covariates. For birth defects with three or four exposed cases, crude ORs and Fisher’s 
exact CIs were calculated. ORs are not shown for birth defects with fewer than three 
exposed cases. ORs were used to estimate relative risk. To reduce etiologic heterogeneity 
within case groups, we separately examined isolated defects for each birth defect category.
When sample size permitted, crude and adjusted ORs and CIs were estimated for the 
association between autoimmune medication use and birth defects. Specifically, we 
examined any use of an immune modifier/suppressant, any use of a glucocorticoid in the 
absence of immune modifier/suppressant use, and “untreated” autoimmune disease. Infants 
of mothers with autoimmune disease who were taking thyroid medication, but not on an 
immune modifier/suppressant or a glucocorticoid were excluded from the medication 
analysis (45 cases, 14 controls), as were 1170 infants (925 cases, 245 controls) of mothers 
without autoimmune disease who reported using an immune modifier/suppressant (n = 13), 
glucocorticoid (n = 1149), or thyroid medication (n = 8). The reference group was infants of 
mothers without autoimmune disease who did not report using one of these medications.
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We examined whether the association between autoimmune disease and birth defects (all 
cases and isolated cases only) varied by maternal BMI and folic acid-containing supplement 
use. Additive interaction was assessed by calculating the excess relative risk due to 
interaction along with the 95% CIs using a logistic regression model adjusted for the 
covariates (Hosmer and Leme-show, 1992). Analyses were performed using SAS software, 
version 9.3 (SAS Corporation, Cary, NC).
Results
After excluding 1418 infants with uncommon CHD associations or complex birth defects, 
950 infants of mothers with possible autoimmune disease (710 cases, 240 controls), 280 
infants of mothers with type 1 diabetes (252 cases, 28 controls), and 348 infants of mothers 
with type 2 diabetes (313 cases, 35 controls), 35,013 infants (25,116 cases, 9897 controls) 
remained in the analysis.
Overall, 373 mothers reported autoimmune disease: 279 (1.1%) case and 94 (0.9%) control 
infants. Table 1 outlines the distribution of covariates among controls by autoimmune 
disease status. Table 2 lists the number of mothers with each reported autoimmune disease. 
Twelve mothers reported two distinct autoimmune diseases. Systemic autoimmune disease 
was reported by 183 mothers (49% of all autoimmune disease; 135 mothers of case infants, 
48 mothers of control infants). Six mothers reported having two systemic autoimmune 
conditions.
The associations between maternal autoimmune disease (irrespective of medication use) and 
the 28 noncardiac birth defects in the main analysis are presented in Table 3, along with the 
associations between systemic autoimmune disease (a subset of mothers with autoimmune 
disease) and noncardiac birth defects. For all cases (both isolated and not), infants of 
mothers with autoimmune disease had more than four times the estimated risk of 
encephalocele compared with infants of mothers without autoimmune disease (OR = 4.64; 
95% CI, 1.95–11.04). For isolated birth defects, infants of mothers with autoimmune disease 
had significantly increased risk of encephalocele (OR = 6.11; 95% CI, 2.54–14.68) and 
hydrocephaly (OR = 2.40; 95% CI, 1.03–5.59). In the exploratory analysis, infants of 
mothers with autoimmune disease had an increased risk of isolated cloacal exstrophy (OR = 
7.11; 95% CI, 1.39–22.80). No other defect in the exploratory analysis had more than one 
exposed case.
Maternal systemic autoimmune disease was associated with an increased risk of 
encephalocele (OR = 8.54; 95% CI, 3.25–22.38), cleft palate (OR = 1.94; 95% CI, 1.04–
3.62), isolated encephalocele (OR = 11.17; 95% CI, 4.22–29.55), isolated cleft palate (OR = 
2.12; 95% CI, 1.11–4.05), and isolated transverse limb deficiencies (OR = 2.55; 95% CI, 
1.08–6.05). Neither autoimmune disease nor systemic autoimmune disease were 
significantly associated with an increased risk of a CHD (Table 4).
We examined whether the associations between maternal autoimmune disease and each birth 
defect differed across levels of maternal BMI and folic acid use (data not shown). We did not 
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find a difference in any association on the additive scale by either (relative risk due to 
interaction 95% CI contained 0).
Among all mothers, 95 (69 case mothers, 26 control mothers) reported taking an immune-
modifying/suppressing agent any time during pregnancy and 1224 mothers (966 case 
mothers, 258 control mothers) reported using a glucocorticoid. Eighty-two mothers (86.3%) 
who used an immune modifier/suppressant had an autoimmune disease: 67 (81.7%) reported 
using one and 15 (18.3%) reported taking two of these medications (Table 5). Slightly less 
than half of these mothers reported taking an immune modifier/suppressant throughout 
pregnancy (39/82, 48%), while the same number reported taking an immune modifier/
suppressant during the first trimester only. Mothers with autoimmune disease also reported 
taking anti-thyroid medication (n = 12), thyroid hormone (n = 54), nonsteroidal anti-
inflammatory drug (n = 176), opioids (n = 39), and anticoagulants (n = 11).
Infants of mothers with autoimmune disease who reported taking an immune modifier/
suppressant had over seven times the estimated risk of encephalocele (OR = 7.26; 95% CI, 
1.37–24.61; Table 6) and three times the risk of ASD (OR = 3.01; 95% CI, 1.16–7.80). 
Glucocorticoid use among mothers with autoimmune disease and “untreated” autoimmune 
disease were not significantly associated with any birth defect. However, the OR for 
encephalocele remained elevated among the “untreated” mothers with autoimmune disease, 
although this was based on three “untreated” case mothers and had wide CIs (OR = 3.31; 
95% CI, 0.65–10.45). The majority of transverse limb deficiencies occurred among infants 
whose mothers were “untreated” (8/10 infants whose mothers had autoimmune disease). We 
observed an increased risk that approached statistical significance for transverse limb 
deficiency among these “untreated” mothers with autoimmune disease compared with 
“untreated” mothers without autoimmune disease (OR = 2.35; 95% CI, 0.99–5.57), similar 
to the magnitude and direction seen in the significant transverse limb deficiency findings 
with systemic autoimmune disease.
Discussion
In our analysis of over 35,000 mothers in the NBDPS, 1.1% of case mothers and 0.9% of 
control mothers reported an autoimmune disease. We did not find increased risk associated 
with autoimmune disease or its treatment for the majority of birth defects examined. We 
found statistically significant associations between maternal autoimmune disease and 
encephalocele, hydrocephaly, and cloacal exstrophy, with OR estimates ranging from 2.4 to 
7.1. Maternal systemic autoimmune disease was associated with encephalocele, cleft palate, 
and transverse limb deficiency, with OR estimates ranging from 1.9 to 11.2. We also 
observed statistically significant associations between immune modifier/suppressant use and 
encephalocele and ASD.
Our findings for encephalocele were similar regardless of how we examined the outcome 
(all cases vs. isolated) or the exposure (autoimmune vs. systemic disease). Estimates for 
encephalocele were further from the null when the analysis was restricted to isolated cases, 
and even further when we examined the subset with systemic disease. If the estimate 
represents a true increase in risk attributable to autoimmune disease, based on an estimated 
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prevalence of 0.84 infants with encephalocele per 10,000 live births, an OR of 4.64 would 
translate to a potential increase in absolute risk from 1 infant with encephalocele per 11,905 
live births to 1 in 2566 live births among women with autoimmune disease. The potential 
increase in risk would be even greater (1 in 1394) if we considered mothers with systemic 
autoimmune disease (Parker et al., 2010).
Autoimmune disease has been connected to several adverse fetal outcomes, yet the literature 
is sparse on the association between autoimmune disease and the risk of specific birth 
defects. Limited information is also available about the safety of immunosuppressive agents 
in pregnancy, and the debate about the association of these medications with specific birth 
defects is ongoing (Kim et al., 2014). For many immunosuppressive agents, the 
recommendations for use during pregnancy differ (Ostensen et al., 2006). Often the findings 
of increased risk associated with specific immunosuppressive medications are based on case 
reports or case series, or the published findings provide contradictory estimates of the risk of 
birth defects.
Our analysis had to group immune modifiers/suppressants together due to small numbers, so 
we could not separate the effects of individual medications. We separately examined infants 
whose mothers took a glucocorticoid medication in the absence of an immune modifier/
suppressant. While maternal use of glucocorticoids has been associated with oral clefts, a 
NBDPS study recently found no association (Skuladottir et al., 2014). We were only able to 
calculate an OR for the association between glucocorticoid use among mothers with 
autoimmune disease and one birth defect (ASD); the elevated OR was not statistically 
significant.
Our study has several strengths. NBDPS clinical geneticists use strict ascertainment criteria 
and detailed methods to classify cases (Rasmussen et al., 2003). Given the large size of the 
NBDPS, we were able to separately evaluate the associations between etiologically 
homogenous birth defect categories and both autoimmune disease and medication use. We 
were also able to separately analyze isolated cases. Lastly, the NBDPS is a population-based 
study, and the controls represent the same base population as the cases (Cogswell et al., 
2009).
Our study has several limitations. The NBDPS relies on retrospective self-reported disease 
status and medication use during pregnancy, making recall bias a potential concern. 
However, we observed positive associations between maternal autoimmune disease and 
some, but not all, birth defects. If recall bias strongly influenced the results, we would have 
expected elevated ORs for a wider range of birth defects than was found.
A few factors could have impacted our ascertainment of autoimmune disease. First, the 
NBDPS did not ask specifically about autoimmune disease status, instead relying on an 
open-ended question to identify mothers with autoimmune disease. This could have led to 
under-ascertainment of autoimmune disease. Second, the NBDPS questionnaire changed in 
2006, so that autoimmune disease was mentioned in the question prompt. We found that 
mothers interviewed after this change were more likely to report autoimmune disease than 
mothers interviewed with the older questionnaire, but reporting of immune-modifier/
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suppressant drug use did not differ. The proportions of cases and controls who reported 
autoimmune disease were the same in the two time periods, so any misclassification of 
exposure should be nondifferential.
Lastly, we excluded women with diabetes to examine the effect of other autoimmune 
diseases on the risk for birth defects. We found that 1.1% of NBDPS mothers (1.1% of 
cases, 0.9% of controls) reported autoimmune disease. Other published estimates of 
autoimmune disease in the general population are much higher, ranging from 3.2 to 9% 
(Jacobson et al., 1997; Eaton et al., 2007; Cooper et al., 2009; Sardu et al., 2012). Our 
findings are more in line with a Danish study of women aged 14 or older (Khashan et al., 
2011). Our study and the study by Khashan et al. only included women of childbearing age. 
Khashan et al. reported 2.4% of women had an autoimmune disease. While this is higher 
than our findings, this is largely due to our exclusion of diabetics. Khashan et al. included 
type 1 diabetics, which was the most common autoimmune disease in their study, with a 
prevalence of 9.75 per 1000. If we had included infants of women with type 1 diabetes in 
our analysis, we would have found that 1.9% of infants (2.1% cases, 1.2% of controls) had a 
mother with autoimmune disease.
Despite the large size of the NBDPS, our analysis was restricted by small numbers in several 
ways. The number of mothers with autoimmune disease was small, and autoimmune 
medication use was even rarer. Thus, we analyzed a composite variable for both autoimmune 
disease and autoimmune medications instead of looking at risks of specific autoimmune 
diseases/medications. We were able to collect information on the distribution of specific 
autoimmune diseases and medications reported by mothers. Yet, we combined disease and 
treatments together to obtain a sufficient sample size. We were also limited in our ability to 
control for confounding by indication.
While we did not find a difference in any association on the additive scale by either BMI or 
folic acid use, we cannot be certain that additive interaction does not exist because small 
numbers and limited power may have impacted our ability to detect the presence of additive 
interaction. Due to small numbers of cases, we may not have been able to detect a true 
increase in risk for some birth defect groups. Our findings may be due to chance. The main 
analysis included 99 statistical tests; approximately five statistically significant associations 
would be expected by chance alone. We observed eight such associations and found robust 
associations between our exposure and encephalocele.
We examined associations between autoimmune disease and its treatment and a wide range 
of birth defects, finding that the majority of birth defects were not associated with 
autoimmune disease or its treatment. While this is reassuring, our findings do suggest an 
association between maternal autoimmune disease and encephalocele. However, 
encephalocele is rare; the increased risk we observed, if true and attributable to autoimmune 
disease, would translate to a risk of approximately 1 in 2500 live births compared with a risk 
in the general population of approximately 1 in 12,000 births. Other long-term, population-
based studies are needed to confirm these findings and better evaluate the association 
between specific autoimmune disease and treatments and individual birth defects.
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TABLE 1
Selected Characteristics of Controls (n = 9897) with and without Autoimmune Disease, National Birth Defects 







n (%) p Value
Maternal age (years)
 ≤29 30 (32) 6044 (62)
 30–34 37 (39) 2449 (25) <0.001
 ≥35 27 (29) 1310 (13)
Race/ethnicity
 Non-Hispanic white 83 (88) 5638 (58) <0.001
 Other 11 (12) 4155 (42)
Education (years)
 ≤12 14 (15) 3993 (42) <0.001
 >12 79 (85) 5568 (58)
Parity
 0 or 1 78 (83) 7100 (73) 0.026
 2 or more 16 (17) 2665 (27)
Pre-pregnancy BMI
 <18.5 4 (4) 514 (6)
 18.5–24.9 51 (55) 5071 (54) 0.929
 25–29.9 23 (25) 2137 (23)
 ≥30 15 (16) 1612 (17)
Smokingb
 Yes 14 (15) 1761 (18) 0.413
 No 79 (85) 7833 (82)
Alcoholb
 Yes 53 (57) 3496 (37) <0.001
 No 40 (43) 6060 (63)
Folic acid-containing supplement usec
 Yes 71 (76) 5096 (53) <0.001
 No 23 (24) 4468 (47)
a
Numbers vary because of missing values.
b
From 1 month before pregnancy through the third month of pregnancy.
c
From 1 month before pregnancy through the first month of pregnancy.
BMI, body mass index (weight in kilograms/height in meters2).
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TABLE 2
Autoimmune Conditions Reported by Mothers of Cases and Controls, National Birth Defects Prevention 
Study 1997 to 2009
Condition (ICD code)
All mothers (n = 373)
n (%)a
Case mothers (n = 
279)
n (%)a
Control mothers (n = 
94)
n (%)a
Graves’ disease (242) 33 (9) 25 (9) 8 (9)
Hashimoto’s thyroiditis (245.2) 31 (8) 26 (9) 5 (5)
Thyroid disease, autoimmune, unspecified (246.9) 1 (< 1) 1 (< 1) 0
Addison’s disease (255 .41) 1 (< 1) 1 (< 1) 0
Pernicious anemia (281) 5 (1) 3 (1) 2 (2)
Hemolytic anemia, autoimmune (283) 2 (1) 1 (<1) 1 (1)
Immune/idiopathic thrombocytopenic purpura (287.31) 13 (4) 5 (2) 8 (9)
Antiphospholipid antibody syndrome (289.81)b 10 (3) 9 (3) 1 (1)
Protein S deficiency (289.81) 1 (< 1) 1 (< 1) 0
Multiple sclerosis (340) 28 (8) 24 (9) 4 (4)
Guillain-Barre syndrome (357) 3 3 (1) 1 (< 1) 2 (2)
Myasthenia gravis (358) 3 (1) 3 (1) 0
Rheumatic fever (390) 2 (1) 2 (1) 0
Crohn’s disease (555.9)b 29 (8) 20 (7) 9 (10)
Ulcerative proctitis (556.2)b 1 (< 1) 1 (< 1) 0
Ulcerative colitis (556.9)b 39 (11) 27 (10) 12 (13)
Inflammatory bowel disease (558.9)b 2 (1) 2 (1) 0
Hepatitis, autoimmune (571.42) 1 (< 1) 0 1 (1)
Celiac disease (579) 19 (5) 15 (5) 4 (4)
Interstitial cystitis (595.1) 15 (4) 14 (5) 1 (1)
Dermatitis herpetaformis (694) 1 (< 1) 1 (< 1) 0
Psoriatic arthritis (696)b 2 (1) 2 (1) 0
Psoriasis (696.1) 31 (8) 21 (8) 10 (11)
Alopecia universalis/areata (704; 704.01, 704.09) 3 (1) 2 (1) 1 (1)
Vitiligo (709.01) 3 (1) 3 (1) 0
Systemic lupus erythematosus; scleroderma; Sjögren’s 
syndrome; connective tissue disease (710, 710.1, 710.2, 710.9)b
46 (12) 36 (13) 10 (11)
Rheumatoid arthritis; juvenile rheumatoid arthritis (714; 714.3)b 57 (15) 42 (15) 15 (16)
Ankylosing spondylitis (720)b 3 (1) 1 (< 1) 2 (2)
Twelve mothers reported two autoimmune conditions (10 mothers of case infants, 2 mothers of control infants).
a
Percentages do not total 100.
b
Considered a systemic autoimmune disease.
ICD, International Classification of Diseases (9th Revision).
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TABLE 5
Autoimmune Medication Usea among Mothers with Autoimmune Disease (n = 373), National Birth Defects 
Prevention Study, 1997 to 2009
Medications All mothers with autoimmune disease Mothers of case infants Mothers of control infants
Immune modifiers/suppressants 82b 61 21
Synthetic agents
 Hydroxychloroquine 17 14 3
 Methotrexate 9 7 2
 Cyclophosphamide 1 1 0
 Azathioprine 6 3 3
 Cyclosporine 1 1 0
 Mycophenolate 2 2 0
 Sulfasalazine 10 5 5
 Mesalamine 34 24 10
 Methoxsalen 1 1 0
 Biologic agents
 TNF-inhibitorsc 7 6 1
 Other biologicsd 9 7 2
Other
 Glucocorticoidse 73 55 18
a
Medication use includes those who reported taking the medication at any time in the 3 months before through the end of pregnancy, as well as 
those who reported taking the medication in that time period, but the dates of use were unknown. No mothers reported taking acitretin, hydroxyurea 
mercaptopurine, or rituximab.
b
Reported taking at least one immune modifier/suppressant; 15 mothers (10 case mothers and 5 control mothers) reported taking two of these 
medications.
c
Category includes infliximab, adalimumab, and etanercept.
d
Category includes interferon beta-1a, interferon beta-1b, and glatiramer acetate.
e
Glucocorticoids includes all glucocorticoids except three taken only for asthma (fluticasone, beclomethasone, and mometasone). Forty of these 
mothers reported glucocorticoid use in the absence of an immune modifier/suppressant.
TNF, tumore necrosis factor.
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